NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00003-4160-14 | 00003-4160 | Repotrectinib | Augtyro | 160.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Oral | Nov 1, 2024 | In Use | |
00310-9500-02 | 00310-9500 | Capivasertib | TRUQAP | 160.0 mg/1 | Chemotherapy | AKT Inhibitor | AKT1/2/3 | Oral | Oct 18, 2024 | In Use | |
00003-4160-60 | 00003-4160 | Repotrectinib | Augtyro | 160.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Oral | Nov 1, 2024 | In Use | |
73555-0502-00 | 73555-0502 | Revumenib | Revuforj | 160.0 mg/1 | Chemotherapy | Enzyme Inhibitor | KMT2A | Oral | Nov 15, 2024 | In Use | |
00002-5562-60 | 00002-5562 | Selpercatinib | RETEVMO | 160.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, RET | Oral | Apr 10, 2024 | In Use | |
69097-0372-47 | 69097-0372 | Docetaxel Anhydrous | Docetaxel Anhydrous | 160.0 mg/16mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 24, 2018 | Aug 26, 2020 | In Use |
83831-0103-16 | 83831-0103 | Docetaxel | DOCIVYX | 160.0 mg/16mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 9, 2024 | In Use | |
70121-1223-01 | 70121-1223 | Docetaxel | Docetaxel | 160.0 mg/8mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan 19, 2018 | In Use | |
43598-0389-57 | 43598-0389 | Docetaxel | Docetaxel | 160.0 mg/8mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Apr 22, 2019 | In Use | |
00955-1022-08 | 00955-1022 | Docetaxel | Docetaxel | 160.0 mg/8mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 23, 2016 | In Use | |
72485-0216-08 | 72485-0216 | Docetaxel | Docetaxel | 160.0 mg/8mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan 15, 2020 | In Use | |
47335-0939-40 | 47335-0939 | Docetaxel | Docetaxel | 160.0 mg/8mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Nov 26, 2020 | In Use | |
65597-0504-04 | 65597-0504 | QUIZARTINIB | VANFLYTA | 17.7 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | Jul 20, 2023 | In Use | |
65597-0504-28 | 65597-0504 | QUIZARTINIB | VANFLYTA | 17.7 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | Jul 20, 2023 | In Use | |
00781-3201-94 | 00781-3201 | Levoleucovorin | Levoleucovorin | 175.0 mg/17.5mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Apr 23, 2015 | Apr 30, 2023 | No Longer Used |
16714-0890-01 | 16714-0890 | LEVOLEUCOVORIN | LEVOLEUCOVORIN | 175.0 mg/17.5mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Sep 26, 2018 | In Use | |
43598-0771-11 | 43598-0771 | LEVOLEUCOVORIN | LEVOLEUCOVORIN | 175.0 mg/17.5mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Sep 26, 2018 | In Use | |
68152-0112-01 | 68152-0112 | levoleucovorin | KHAPZORY | 175.0 mg/3.5mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Jan 2, 2019 | In Use | |
72893-0004-01 | 72893-0004 | Levoleucovorin | KHAPZORY | 175.0 mg/3.5mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Jan 2, 2019 | In Use | |
64980-0337-14 | 64980-0337 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Mar 17, 2017 | In Use | |
00054-0324-06 | 00054-0324 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Mar 24, 2016 | Mar 24, 2016 | No Longer Used |
00085-1430-04 | 00085-1430 | Temozolomide | Temodar | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 11, 1999 | In Use | |
47335-0930-74 | 47335-0930 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
42737-0105-14 | 42737-0105 | temozolomide | TEMOZOLOMIDE | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec 31, 2018 | Jan 24, 2019 | In Use |
62175-0244-19 | 62175-0244 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 10, 2016 | In Use |
Found 11561 results — Export these results